+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032- Product Image
Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032- Product Image
Sale

Respiratory Tract Infection Therapeutic Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012375
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Tract Infection Therapeutic Market is projected to reach USD 54.74 Billion in 2026. It is expected to continue growing at a CAGR of 8.20%, reaching USD 89.34 Billion by 2032.

Respiratory tract infection therapeutics remain a critical healthcare segment because acute respiratory infections continue to account for substantial morbidity, hospitalization, antibiotic use, and mortality worldwide. The World Health Organization identifies lower respiratory infections among the leading infectious causes of death globally, while influenza, RSV, COVID-19, bacterial pneumonia, sinusitis, bronchitis, and acute exacerbations of chronic airway disease continue to shape prescribing behavior across inpatient and outpatient care.

Demand is being reinforced by aging populations, immunocompromised patient growth, urban air pollution, antimicrobial resistance, and higher use of molecular diagnostics that can distinguish viral, bacterial, and atypical pathogens. The competitive landscape is shifting toward targeted antivirals, next-generation antibiotics, monoclonal antibodies, host-directed therapies, and evidence-based antimicrobial stewardship, making clinical differentiation and payer-aligned outcomes central to market success.

Transformative Shifts in the Therapeutics Landscape

The respiratory tract infection therapeutics landscape is moving from broad empiric treatment toward pathogen-specific, risk-stratified care. Rapid PCR panels, point-of-care testing, antigen testing, and improved genomic surveillance are reducing diagnostic uncertainty and supporting more precise use of antivirals and antibiotics. This transition is especially important as the CDC and WHO continue to identify antimicrobial resistance as a major public health threat, with respiratory infections representing a frequent driver of antibiotic prescribing.

Therapeutic innovation is also being shaped by lessons from COVID-19, where accelerated trials, decentralized monitoring, platform studies, and adaptive regulatory pathways demonstrated how quickly respiratory medicines can move from discovery to deployment when public health urgency is high. The result is a more integrated model in which diagnostics, therapeutics, real-world evidence, pharmacovigilance, and stewardship programs increasingly determine clinical adoption and commercial value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across respiratory tract infection therapeutics by improving target identification, compound screening, patient stratification, and trial enrollment. AI-enabled modeling can analyze genomic, epidemiological, imaging, and electronic health record data to identify emerging variants, predict disease severity, and support faster selection of therapeutic candidates.

In commercial and clinical operations, AI is strengthening demand planning, antimicrobial stewardship, and pharmacovigilance. Hospitals and payers can use predictive analytics to reduce unnecessary antibiotic use, while manufacturers can use machine learning to monitor safety signals, identify treatment-response patterns, and optimize real-world evidence generation. These capabilities are especially relevant in influenza, RSV, COVID-19, and drug-resistant bacterial pneumonia, where timely intervention directly affects outcomes.

Key Regional Insights

Asia-Pacific is a high-priority region due to its large population base, high respiratory infection burden, dense urban centers, and expanding healthcare access. China, India, Japan, South Korea, and Australia are strengthening diagnostic capacity and domestic pharmaceutical capabilities, while seasonal influenza, pneumonia, tuberculosis overlap, air pollution exposure, and post-pandemic respiratory surveillance continue to influence therapeutic demand.

North America remains a leading region for advanced respiratory tract infection therapeutics, supported by established regulatory pathways, high diagnostic adoption, strong hospital infrastructure, immunization programs, and reimbursement for innovative medicines. Latin America is expanding access to antivirals and antibiotics, although affordability, fragmented procurement, and uneven diagnostic capacity continue to influence uptake across Brazil, Mexico, and other major markets.

Europe benefits from coordinated public health guidance, robust antimicrobial stewardship, and centralized regulatory oversight, with Germany, France, Italy, Spain, and the United Kingdom driving demand for evidence-based respiratory infection care. The Middle East is investing in hospital modernization and infectious disease preparedness, particularly across Gulf economies, while Africa faces the dual challenge of high pneumonia burden and limited access to diagnostics, oxygen, antibiotics, and newer therapeutics.

Key Group Insights

ASEAN markets are benefiting from expanding universal health coverage, rising private healthcare investment, and stronger infectious disease surveillance after COVID-19. Demand is concentrated around affordable antibiotics, influenza treatments, and hospital-based pneumonia care, with Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines showing different levels of diagnostic and reimbursement maturity.

The GCC is advancing hospital infrastructure, specialty care, and health security programs, creating opportunities for premium antivirals, injectable antibiotics, and rapid diagnostics-linked treatment pathways. The European Union continues to prioritize antimicrobial resistance containment, joint health preparedness, and evidence-based prescribing, which favors therapies with clear clinical value, safety evidence, and stewardship compatibility.

BRICS countries represent a major volume opportunity due to large patient populations, high respiratory disease burden, and expanding domestic pharmaceutical production. G7 countries lead adoption of innovative respiratory therapeutics through strong regulatory science, payer scrutiny, guideline-based care, and high use of clinical evidence. NATO member markets, while not a healthcare bloc, share strategic emphasis on medical readiness, supply chain resilience, and preparedness for respiratory outbreaks that can affect workforce continuity, emergency response, and defense readiness.

Key Country Insights

The United States leads innovation in respiratory tract infection therapeutics through strong biomedical research activity, established regulatory pathways, and high utilization of advanced diagnostics. Canada emphasizes guideline-driven care, immunization, and stewardship, while Mexico balances growing healthcare demand with access and affordability considerations. Brazil is the largest Latin American opportunity, supported by population scale, public procurement systems, and infectious disease infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature markets where payer evidence, antimicrobial stewardship, national treatment guidelines, and hospital protocols shape adoption. Russia maintains demand across antibiotics and hospital infection care, although market access can be affected by geopolitical, regulatory, and supply chain constraints.

China and India are central to global demand because of population scale, domestic manufacturing, and high respiratory infection incidence. Japan favors clinically proven, high-quality therapeutics in an aging society, while South Korea combines advanced diagnostics with strong hospital systems and rapid technology adoption. Australia maintains high standards for prescribing, surveillance, and reimbursement, supporting targeted adoption of therapeutics with demonstrated outcome benefits.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated therapies that address clearly defined unmet needs such as severe RSV disease, influenza complications, COVID-19 in high-risk patients, drug-resistant bacterial pneumonia, and respiratory infections in immunocompromised populations. Development strategies should combine pathogen-specific efficacy, safety in vulnerable groups, resistance monitoring, and practical dosing advantages that support adherence and hospital workflow.

Commercial teams should align launches with rapid diagnostics, antimicrobial stewardship, real-world evidence, and payer outcomes. Partnerships with hospitals, diagnostic providers, public health agencies, and regional distributors can improve treatment access while supporting responsible use. Supply chain resilience should be treated as a strategic requirement, especially for antibiotics, antivirals, monoclonal antibodies, and critical care injectables.

Research Methodology

The respiratory tract infection therapeutics assessment is developed through triangulated secondary research, primary expert validation, regulatory review, and competitive intelligence. Secondary sources include WHO, CDC, FDA, EMA, ECDC, national health agencies, peer-reviewed journals, clinical trial registries, public procurement references, treatment guidelines, and pharmacovigilance resources.

The methodology combines epidemiology, disease burden analysis, treatment guideline review, pipeline assessment, pricing and reimbursement evaluation, regulatory pathway analysis, and regional access assessment. Insights are validated through cross-source comparison to minimize bias and ensure that conclusions reflect verifiable clinical, regulatory, epidemiological, and commercial evidence without relying on unsupported assumptions.

Conclusion

Respiratory tract infection therapeutics are entering a more precise, data-enabled, and stewardship-driven phase. The market is shaped by persistent disease burden, aging demographics, antimicrobial resistance, seasonal outbreaks, air pollution, healthcare preparedness, and continued investment in respiratory surveillance after the COVID-19 pandemic.

Organizations that integrate diagnostic-linked treatment, AI-enabled development, robust evidence generation, responsible antimicrobial use, and resilient access strategies will be best positioned to create value. The next phase of growth will favor therapies that improve outcomes, reduce inappropriate antimicrobial use, and address the needs of high-risk patient populations across diverse healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Respiratory Tract Infection Therapeutic Market, by Infection Type
7.1. Introduction
7.2. Lower Respiratory Tract Infection
7.2.1. Pneumonia
7.2.2. Bronchitis
7.2.3. Bronchiolitis
7.2.4. Tuberculosis
7.3. Upper Respiratory Tract Infection
7.3.1. Common Cold
7.3.2. Sinusitis
7.3.3. Pharyngitis
7.3.4. Laryngitis
8. Respiratory Tract Infection Therapeutic Market, by Pathogen Type
8.1. Introduction
8.2. Bacterial Infections
8.2.1. Streptococcus pneumoniae
8.2.2. Haemophilus influenzae
8.2.3. Mycoplasma pneumoniae
8.3. Viral Infections
8.3.1. Influenza virus
8.3.2. Respiratory Syncytial Virus (RSV)
8.3.3. Adenovirus
8.3.4. Coronavirus
8.4. Fungal Infections
8.4.1. Aspergillus
8.4.2. Pneumocystis jirovecii
9. Respiratory Tract Infection Therapeutic Market, by Therapeutic Type
9.1. Introduction
9.2. Antibiotics
9.2.1. Penicillins
9.2.2. Cephalosporins
9.2.3. Macrolides
9.2.4. Fluoroquinolones
9.3. Antivirals
9.3.1. Neuraminidase Inhibitors
9.3.2. Polymerase Inhibitors
9.3.3. Monoclonal Antibodies
9.4. Symptomatic Treatments
9.5. Bronchodilators
9.6. Immunotherapies
10. Respiratory Tract Infection Therapeutic Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.2.1. Capsules
10.2.2. Tablets
10.2.3. Syrups
10.3. Parenteral
10.3.1. Intravenous
10.3.2. Intramuscular
10.3.3. Subcutaneous
11. Respiratory Tract Infection Therapeutic Market, by Patient Type
11.1. Introduction
11.2. Adults
11.3. Geriatrics
11.4. Pediatrics
12. Respiratory Tract Infection Therapeutic Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Ambulatory Surgical Centers
12.5. Homecare Settings
13. Respiratory Tract Infection Therapeutic Market, by Distribution Channel
13.1. Introduction
13.2. Online
13.3. Offline
14. Respiratory Tract Infection Therapeutic Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Respiratory Tract Infection Therapeutic Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Respiratory Tract Infection Therapeutic Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Abbott Laboratories
18.2. Alkem Laboratories Limited
18.3. AstraZeneca PLC
18.4. Boehringer Ingelheim GmbH
18.5. Cadila Healthcare Limited
18.6. Cipla Limited
18.7. F. Hoffmann-La Roche AG
18.8. GlaxoSmithKline plc
18.9. Glenmark Pharmaceuticals Limited
18.10. Hikma Pharmaceuticals PLC
18.11. Intas Pharmaceuticals Limited
18.12. Lupin Limited
18.13. Merck & Co., Inc.
18.14. Mylan Inc. by Viatris Inc.
18.15. Novartis International AG
18.16. Pfizer Inc.
18.17. Sanofi S.A.
18.18. Steris Healthcare Pvt. Ltd.
18.19. Teva Pharmaceutical Industries Ltd
List of Figures
FIGURE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL LOWER RESPIRATORY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PNEUMONIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PNEUMONIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PNEUMONIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL BRONCHITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL BRONCHITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL BRONCHITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL BRONCHIOLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BRONCHIOLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BRONCHIOLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL UPPER RESPIRATORY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL UPPER RESPIRATORY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL UPPER RESPIRATORY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL COMMON COLD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL COMMON COLD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL COMMON COLD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SINUSITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SINUSITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SINUSITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PHARYNGITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PHARYNGITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PHARYNGITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL LARYNGITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL LARYNGITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL LARYNGITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL STREPTOCOCCUS PNEUMONIAE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL STREPTOCOCCUS PNEUMONIAE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL STREPTOCOCCUS PNEUMONIAE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HAEMOPHILUS INFLUENZAE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HAEMOPHILUS INFLUENZAE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HAEMOPHILUS INFLUENZAE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL MYCOPLASMA PNEUMONIAE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MYCOPLASMA PNEUMONIAE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MYCOPLASMA PNEUMONIAE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CORONAVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CORONAVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CORONAVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ASPERGILLUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ASPERGILLUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ASPERGILLUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PNEUMOCYSTIS JIROVECII MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PNEUMOCYSTIS JIROVECII MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PNEUMOCYSTIS JIROVECII MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SYMPTOMATIC TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 216. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 217. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 218. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 219. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 220. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 221. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 222. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 223. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 224. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 225. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 226. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 228. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 229. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 230. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 234. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 235. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 236. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 250. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 251. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 252. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 253. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 254. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 255. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 256. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 257. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 258. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 259. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 260. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 262. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 263. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 264. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 266. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 267. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 269. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 270. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 271. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 272. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 273. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 274. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 275. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 276. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 277. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 278. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 280. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 281. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 282. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 284. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 285. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 286. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 287. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 288. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 289. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 290. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 291. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 292. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 293. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 294. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 295. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 297. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 298. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 299. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2017-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 319. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 320. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 321. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 322. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 323. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BACTERIAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 324. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY VIRAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 325. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 326. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET S

Companies Mentioned

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Steris Healthcare Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 54.74 Billion
Forecasted Market Value ( USD ) by 2032 $ 89.34 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Hospital Infection Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hospital Infection Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Respiratory Tract Infection Treatment Market - Product Image

Respiratory Tract Infection Treatment Market

  • Report
  • 150 Pages
  • Global
From
Upper Respiratory Tract Infection Treatment - Global Strategic Business Report - Product Image

Upper Respiratory Tract Infection Treatment - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2026-2034 - Product Image

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2026-2034

  • Report
  • 141 Pages
  • Global
From
2026 Upper Respiratory Tract Infection Treatment Market Growth Trends and Forecast 2025-2034 - Product Image

2026 Upper Respiratory Tract Infection Treatment Market Growth Trends and Forecast 2025-2034

  • Report
  • 160 Pages
  • Global
From

About the Respiratory Tract Infection Drug Market

The Respiratory Tract Infection Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat infections of the respiratory tract, such as bronchitis, pneumonia, and sinusitis. These drugs are typically antibiotics, antivirals, and anti-inflammatory medications. They are used to reduce symptoms, prevent complications, and reduce the spread of infection. The Respiratory Tract Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson. Other companies include AbbVie, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.